Real-World Patient Perceptions of GLP-1 RAs and SGLT-2is with Cardiorenal Benefits

被引：0
|
作者：
Lambert, Natalie
Clark, Callahan
McCoy, Rozalina G.
Wong, Alyssa
Cook, David J.
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-618-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
618-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
    Uzoigwe, Chioma
    Liang, Yuanjie
    Whitmire, Sarah
    Paprocki, Yurek
    DIABETES THERAPY, 2021, 12 (05) : 1475 - 1489
  • [32] Pre-genetic screening and the use of GLP-1 RA and SGLT-2i in monogenic diabetes: A real-world audit-based study
    Constantino, M.
    Chobanian, A.
    Twigg, S. M.
    McGill, M.
    Wu, T.
    Middleton, T.
    Tabet, E.
    Mallawaarachchi, A.
    Molloy, L.
    Gauld, A.
    Wong, J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [33] Patient initiation and maintenance of GLP-1 RAs for treatment of obesity
    Patel, Dhiren
    Smith, April
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (10) : 1193 - 1204
  • [34] Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
    Chioma Uzoigwe
    Yuanjie Liang
    Sarah Whitmire
    Yurek Paprocki
    Diabetes Therapy, 2021, 12 : 1475 - 1489
  • [35] Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
    Goncalves, Edison
    Bell, David S. H.
    DIABETES THERAPY, 2018, 9 (03) : 919 - 926
  • [36] REAL-WORLD SAFETY OF SGLT2 INHIBITORS, DPP-4 INHIBITORS, AND GLP-1 AGONISTS IN US VETERANS WITH AND WITHOUT CHRONIC KIDNEY DISEASE
    Narasaki, Yoko
    Kovesdy, Csaba
    You, Amy
    Potukuchi, Praveen
    Dashputre, Ankur
    Sumida, Keichii
    Thomas, Fridtjof
    Streja, Elani
    Kalantar-Zadeh, Kam
    Rhee, Connie
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S121 - S122
  • [37] Changes in Perceptions and Confidence of Health Care Professionals across Medical Specialties Regarding Use of SGLT2 and GLP-1 for Cardiorenal Benefit in Type 2 Diabetes
    Zytnick, Deena
    Woolley, Ryan
    Bruns, Michelle
    Shay, Christina M.
    DIABETES, 2021, 70
  • [38] Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
    Georgianos, Panagiotis I.
    Vaios, Vasilios
    Roumeliotis, Stefanos
    Leivaditis, Konstantinos
    Eleftheriadis, Theodoros
    Liakopoulos, Vassilios
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
  • [39] Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
    Edison Goncalves
    David S. H. Bell
    Diabetes Therapy, 2018, 9 : 919 - 926
  • [40] Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
    Dadwani, Rahul S.
    Wan, Wen
    Skandari, M. Reza
    Huang, Elbert S.
    MDM POLICY & PRACTICE, 2023, 8 (02)
12345